VIRALYTICS LIMITED - Announcements

Currently unlisted. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

VLA	Section 708A Notice		07/02/13	Share
VLA	Appendix 3B		05/02/13	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/13	Share
VLA	Chief Executive Officer Employment Contract Details		24/01/13	Share
VLA	Dr. Malcolm McColl commences as Chief Executive Officer	PRICE SENSITIVE	21/01/13	Share
VLA	Cancer technology & commercialisation - LA Presentation		10/01/13	Share
VLA	Section 708A Notice		28/12/12	Share
VLA	Appendix 3B		27/12/12	Share
VLA	Change of Director's Interest Notice x 3		27/12/12	Share
VLA	Share Purchase Plan - Appendix 3B		27/12/12	Share
VLA	Viralytics Share Purchase Plan raises $3.5 Million		21/12/12	Share
VLA	Phase II Melanoma Study Achieves Interim Efficacy Milestone	PRICE SENSITIVE	13/12/12	Share
VLA	New CAVATAK intravenous cancer study scheduled in UK	PRICE SENSITIVE	10/12/12	Share
VLA	Research Report by Van Leeuwenhoeck Research, New York		06/12/12	Share
VLA	Change of Director's Interest Notice x 2		30/11/12	Share
VLA	CAVATAK Bladder Cancer Positive Preliminary Data	PRICE SENSITIVE	29/11/12	Share
VLA	Shareholder Update November 2012		28/11/12	Share
VLA	Appendix 3B		26/11/12	Share
VLA	Share Purchase Plan Pricing		23/11/12	Share
VLA	Letter to Option Holders		22/11/12	Share
VLA	Share Purchase Plan documentation issued to Shareholders		22/11/12	Share
VLA	Reinstatment to Official Quotation	PRICE SENSITIVE	22/11/12	Share
VLA	Underwritten Share Purchase Plan	PRICE SENSITIVE	22/11/12	Share
VLA	Share Purchase Plan Cleansing Notice		22/11/12	Share
VLA	Results of Meeting		22/11/12	Share
VLA	Chairman's Address to Shareholders		22/11/12	Share
VLA	Suspension from Official Quotation	PRICE SENSITIVE	21/11/12	Share
VLA	Trading Halt	PRICE SENSITIVE	19/11/12	Share
VLA	Starpharma VP Dr Malcolm McColl appointed CEO of Viralytics	PRICE SENSITIVE	14/11/12	Share
VLA	Viralytics receives $1.467m R&D tax concession	PRICE SENSITIVE	13/11/12	Share
VLA	Phase I Intravenous Trial Presentation Poster		12/11/12	Share
VLA	CAVATAK Phase I Intravenous Trial Presentation		12/11/12	Share
VLA	CAVATAK Phase I Trial International Conference Presentation	PRICE SENSITIVE	05/11/12	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/12	Share
VLA	Shareholder and Investor Presentation		22/10/12	Share
VLA	Update - Phase 2 Melanoma Clinical Trial - CAVATAK	PRICE SENSITIVE	22/10/12	Share
VLA	Notice of Annual General Meeting/Proxy Form		19/10/12	Share
VLA	Annual Report to shareholders		19/10/12	Share
VLA	Shareholder Newsletter		15/10/12	Share
VLA	Resignation of Company Secretary		08/10/12	Share
VLA	Date of Annual General Meeting		04/10/12	Share
VLA	Appendix 4E and Financial Report	PRICE SENSITIVE	31/08/12	Share
VLA	Change of Director's Interest Notice		10/08/12	Share
VLA	Japanese patent	PRICE SENSITIVE	09/08/12	Share
VLA	Final Director's Interest Notice		06/08/12	Share
VLA	Change of Director's Interest Notice		06/08/12	Share
VLA	US patent	PRICE SENSITIVE	02/08/12	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/12	Share
VLA	Market Update on Viralytics	PRICE SENSITIVE	30/07/12	Share
VLA	Board and Management changes	PRICE SENSITIVE	24/07/12	Share
VLA	INTERNATIONAL BLADDER CANCER COLLABORATION FOR CAVATAKTM		17/07/12	Share
VLA	First Patient commences USA Phase II CALM Study	PRICE SENSITIVE	09/07/12	Share
VLA	Shareholder Briefing in Perth - 2 July 2012		21/06/12	Share
VLA	US presentations		18/06/12	Share
VLA	Bell Potter Life Science conference presentation		24/05/12	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	26/04/12	Share
VLA	China patent - blood cancer	PRICE SENSITIVE	29/03/12	Share
VLA	Appendix 4D and Half Year Report	PRICE SENSITIVE	28/02/12	Share
VLA	Granting of USA patent	PRICE SENSITIVE	15/02/12	Share
VLA	La Jolla exit share register		09/02/12	Share
VLA	Section 708A Notice		25/01/12	Share
VLA	Final conversion of convertible note and appendix 3B		25/01/12	Share
VLA	Section 708A Notice		23/01/12	Share
VLA	Appendix 3B		23/01/12	Share
VLA	First patients commence treatment in US Phase II trial	PRICE SENSITIVE	19/01/12	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	18/01/12	Share
VLA	Section 708A Notice		12/01/12	Share
VLA	Appendix 3B		12/01/12	Share
VLA	Change of Director's Interest Notice x 3		23/12/11	Share
VLA	Share Purchase Plan- Appendix 3B		23/12/11	Share
VLA	Share Purchase Plan raises $4.7 Million		20/12/11	Share
VLA	Additional cancer center - Phase II trial		15/12/11	Share
VLA	Phase II trial - additional cancer center joins trial	PRICE SENSITIVE	09/12/11	Share
VLA	section 708a notice		07/12/11	Share
VLA	Appendix 3B		07/12/11	Share
VLA	CAVATAK and Chemotherapy combination presentation		06/12/11	Share
VLA	Australian patent	PRICE SENSITIVE	01/12/11	Share
VLA	Share Purchase Plan- Shareholders Newsletter		30/11/11	Share
VLA	Share Purchase Plan Cleansing Notice		30/11/11	Share
VLA	Share Purchase Plan - Letter to Option Holders		30/11/11	Share
VLA	Share Purchase Plan - Offer Documentation		30/11/11	Share
VLA	Underwritten Share Purchase Plan	PRICE SENSITIVE	30/11/11	Share
VLA	Trading Halt	PRICE SENSITIVE	28/11/11	Share
VLA	USA patent Notice of Allowance	PRICE SENSITIVE	25/11/11	Share
VLA	Initial Director's Interest Notice		22/11/11	Share
VLA	Eminent US Virologist joins Board of Directors		21/11/11	Share
VLA	Section 708a Notice		15/11/11	Share
VLA	Convertible note - partial conversion		15/11/11	Share
VLA	poster presentation - international melanoma conference		14/11/11	Share
VLA	Results of AGM		14/11/11	Share
VLA	Managing Director's Address to Shareholders		11/11/11	Share
VLA	US Professor of Oncology joins SAB		08/11/11	Share
VLA	Leading International Oncologist joins SAB		02/11/11	Share
VLA	Quarterly Cashflow Report	PRICE SENSITIVE	31/10/11	Share
VLA	Section 708a notice		25/10/11	Share
VLA	Appendix 3B		25/10/11	Share
VLA	US site approval to dose first patient in Phase II trial	PRICE SENSITIVE	20/10/11	Share
VLA	Section 708a announcement		17/10/11	Share
VLA	Appendix 3B - partial conversion of CN		17/10/11	Share
VLA	Abstract Cavatak killing melanoma resistent to new treatment		12/10/11	Share

VLASection 708A Notice
07/02/13		Share
VLAAppendix 3B
05/02/13		Share
VLAAppendix 4C - quarterly
29/01/13	PRICE SENSITIVE	Share
VLAChief Executive Officer Employment Contract Details
24/01/13		Share
VLADr. Malcolm McColl commences as Chief Executive Officer
21/01/13	PRICE SENSITIVE	Share
VLACancer technology & commercialisation - LA Presentation
10/01/13		Share
VLASection 708A Notice
28/12/12		Share
VLAAppendix 3B
27/12/12		Share
VLAChange of Director's Interest Notice x 3
27/12/12		Share
VLAShare Purchase Plan - Appendix 3B
27/12/12		Share
VLAViralytics Share Purchase Plan raises $3.5 Million
21/12/12		Share
VLAPhase II Melanoma Study Achieves Interim Efficacy Milestone
13/12/12	PRICE SENSITIVE	Share
VLANew CAVATAK intravenous cancer study scheduled in UK
10/12/12	PRICE SENSITIVE	Share
VLAResearch Report by Van Leeuwenhoeck Research, New York
06/12/12		Share
VLAChange of Director's Interest Notice x 2
30/11/12		Share
VLACAVATAK Bladder Cancer Positive Preliminary Data
29/11/12	PRICE SENSITIVE	Share
VLAShareholder Update November 2012
28/11/12		Share
VLAAppendix 3B
26/11/12		Share
VLAShare Purchase Plan Pricing
23/11/12		Share
VLALetter to Option Holders
22/11/12		Share
VLAShare Purchase Plan documentation issued to Shareholders
22/11/12		Share
VLAReinstatment to Official Quotation
22/11/12	PRICE SENSITIVE	Share
VLAUnderwritten Share Purchase Plan
22/11/12	PRICE SENSITIVE	Share
VLAShare Purchase Plan Cleansing Notice
22/11/12		Share
VLAResults of Meeting
22/11/12		Share
VLAChairman's Address to Shareholders
22/11/12		Share
VLASuspension from Official Quotation
21/11/12	PRICE SENSITIVE	Share
VLATrading Halt
19/11/12	PRICE SENSITIVE	Share
VLAStarpharma VP Dr Malcolm McColl appointed CEO of Viralytics
14/11/12	PRICE SENSITIVE	Share
VLAViralytics receives $1.467m R&D tax concession
13/11/12	PRICE SENSITIVE	Share
VLAPhase I Intravenous Trial Presentation Poster
12/11/12		Share
VLACAVATAK Phase I Intravenous Trial Presentation
12/11/12		Share
VLACAVATAK Phase I Trial International Conference Presentation
05/11/12	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
24/10/12	PRICE SENSITIVE	Share
VLAShareholder and Investor Presentation
22/10/12		Share
VLAUpdate - Phase 2 Melanoma Clinical Trial - CAVATAK
22/10/12	PRICE SENSITIVE	Share
VLANotice of Annual General Meeting/Proxy Form
19/10/12		Share
VLAAnnual Report to shareholders
19/10/12		Share
VLAShareholder Newsletter
15/10/12		Share
VLAResignation of Company Secretary
08/10/12		Share
VLADate of Annual General Meeting
04/10/12		Share
VLAAppendix 4E and Financial Report
31/08/12	PRICE SENSITIVE	Share
VLAChange of Director's Interest Notice
10/08/12		Share
VLAJapanese patent
09/08/12	PRICE SENSITIVE	Share
VLAFinal Director's Interest Notice
06/08/12		Share
VLAChange of Director's Interest Notice
06/08/12		Share
VLAUS patent
02/08/12	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
31/07/12	PRICE SENSITIVE	Share
VLAMarket Update on Viralytics
30/07/12	PRICE SENSITIVE	Share
VLABoard and Management changes
24/07/12	PRICE SENSITIVE	Share
VLAINTERNATIONAL BLADDER CANCER COLLABORATION FOR CAVATAKTM
17/07/12		Share
VLAFirst Patient commences USA Phase II CALM Study
09/07/12	PRICE SENSITIVE	Share
VLAShareholder Briefing in Perth - 2 July 2012
21/06/12		Share
VLAUS presentations
18/06/12		Share
VLABell Potter Life Science conference presentation
24/05/12		Share
VLAAppendix 4C - quarterly
26/04/12	PRICE SENSITIVE	Share
VLAChina patent - blood cancer
29/03/12	PRICE SENSITIVE	Share
VLAAppendix 4D and Half Year Report
28/02/12	PRICE SENSITIVE	Share
VLAGranting of USA patent
15/02/12	PRICE SENSITIVE	Share
VLALa Jolla exit share register
09/02/12		Share
VLASection 708A Notice
25/01/12		Share
VLAFinal conversion of convertible note and appendix 3B
25/01/12		Share
VLASection 708A Notice
23/01/12		Share
VLAAppendix 3B
23/01/12		Share
VLAFirst patients commence treatment in US Phase II trial
19/01/12	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
18/01/12	PRICE SENSITIVE	Share
VLASection 708A Notice
12/01/12		Share
VLAAppendix 3B
12/01/12		Share
VLAChange of Director's Interest Notice x 3
23/12/11		Share
VLAShare Purchase Plan- Appendix 3B
23/12/11		Share
VLAShare Purchase Plan raises $4.7 Million
20/12/11		Share
VLAAdditional cancer center - Phase II trial
15/12/11		Share
VLAPhase II trial - additional cancer center joins trial
09/12/11	PRICE SENSITIVE	Share
VLAsection 708a notice
07/12/11		Share
VLAAppendix 3B
07/12/11		Share
VLACAVATAK and Chemotherapy combination presentation
06/12/11		Share
VLAAustralian patent
01/12/11	PRICE SENSITIVE	Share
VLAShare Purchase Plan- Shareholders Newsletter
30/11/11		Share
VLAShare Purchase Plan Cleansing Notice
30/11/11		Share
VLAShare Purchase Plan - Letter to Option Holders
30/11/11		Share
VLAShare Purchase Plan - Offer Documentation
30/11/11		Share
VLAUnderwritten Share Purchase Plan
30/11/11	PRICE SENSITIVE	Share
VLATrading Halt
28/11/11	PRICE SENSITIVE	Share
VLAUSA patent Notice of Allowance
25/11/11	PRICE SENSITIVE	Share
VLAInitial Director's Interest Notice
22/11/11		Share
VLAEminent US Virologist joins Board of Directors
21/11/11		Share
VLASection 708a Notice
15/11/11		Share
VLAConvertible note - partial conversion
15/11/11		Share
VLAposter presentation - international melanoma conference
14/11/11		Share
VLAResults of AGM
14/11/11		Share
VLAManaging Director's Address to Shareholders
11/11/11		Share
VLAUS Professor of Oncology joins SAB
08/11/11		Share
VLALeading International Oncologist joins SAB
02/11/11		Share
VLAQuarterly Cashflow Report
31/10/11	PRICE SENSITIVE	Share
VLASection 708a notice
25/10/11		Share
VLAAppendix 3B
25/10/11		Share
VLAUS site approval to dose first patient in Phase II trial
20/10/11	PRICE SENSITIVE	Share
VLASection 708a announcement
17/10/11		Share
VLAAppendix 3B - partial conversion of CN
17/10/11		Share
VLAAbstract Cavatak killing melanoma resistent to new treatment
12/10/11		Share

REFRESH

First 2 3 4 5 6

VIRALYTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available